Pasar al contenido principal

TERAPIAS DIRIGIDAS BASADAS EN EL PERFIL MOLECULAR: MITOCONDRIA Y EJE GAS6/TAM EN CROSSTALK CELULAR

PID2021-123564OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

  • Magnus Grøndal, Sturla
  • Tutusaus, Anna
  • Boix, Loreto
  • Reig, María
  • Blø, Magnus
  • Hodneland, Linn
  • Gausdal, Gro
  • Jackson, Akil
  • García de Frutos, Pablo
  • Lorens, James Bradley
  • Morales, Albert
  • Marí, Montserrat
Background and aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health concern with limited treatment options. AXL, a receptor tyrosine kinase activated by the GAS6 ligand, promotes MASH through activation of hepatic stellate cells and inflammatory macrophages. This study identified cell subsets affected by MASH progression and the effect of AXL inhibition. Methods: Mice were fed chow or different fat-enriched diets to induce MASH, and small molecule AXL kinase inhibition with bemcentinib was evaluated. Gene expression was measured by qPCR. Time-of-flight mass cytometry (CyTOF) used single cells from dissociated livers, acquired on the Fluidigm Helios, and cell populations were studied using machine learning. Results: In mice fed different fat-enriched diets, liver steatosis alone was insufficient to elevate plasma soluble AXL (sAXL) levels. However, in conjunction with inflammation, sAXL increases, serving as an early indicator of steatohepatitis progression. Bemcentinib, an AXL inhibitor, effectively reduced proinflammatory responses in MASH models, even before fibrosis appearance. Utilizing CyTOF analysis, we detected a decreased population of Kupffer cells during MASH while promoting infiltration of monocytes/macrophages and CD8+ T cells. Bemcentinib partially restored Kupffer cells, reduced pDCs and GzmB- NK cells, and increased GzmB+CD8+ T cells and LSECs. Additionally, AXL inhibition enhanced a subtype of GzmB+CD8+ tissue-resident memory T cells characterized by CX3CR1 expression. Furthermore, bemcentinib altered the transcriptomic landscape associated with MASH progression, particularly in TLR signaling and inflammatory response, exhibiting differential cytokine expression in the plasma, consistent with liver repair and decreased inflammation. Conclusion: Our findings highlight sAXL as a biomarker for monitoring MASH progression and demonstrate that AXL targeting shifted liver macrophages and CD8+ T-cell subsets away from an inflammatory phenotype toward fibrotic resolution and organ healing, presenting a promising strategy for MASH treatment., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Projects# RTI2018–095672-B-I00 and PID2021–123564OB-I00 to AM and PG funded by MCIN/AEI/10.13039/501100011033 and co-funded by “ERDF A way of making Europe”. Project# PI19/01410 and PI22/00475 to MM funded by Instituto de Salud Carlos III and co-funded by the European Union “ERDF A way of making Europe”; AGAUR (2021_SGR_490) and CERCA Programme/Generalitat de Catalunya, and Fundació la Marató de TV3 (202133–32).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Prognostic value of soluble AXL in serum from heart failure patients with preserved and reduced left ventricular ejection fraction

  • Cristóbal, Helena
  • Enjuanes Grau, Cristina
  • Batlle, Montserrat
  • Tajes Orduña, Marta
  • Campos, Begoña
  • Francesch Manzano, Josep
  • Moliner Borja, Pedro
  • Farrero, Marta
  • Andrea, Rut
  • Ortiz-Pérez, Jose-Tomás
  • Morales, Albert
  • Sabaté, Manel
  • Comín Colet, Josep
  • García de Frutos, Pablo
Heart failure (HF) is classified according to the degree of reduction in left ventricular ejection fraction (EF) in HF with reduced, mildly reduced, and preserved EF. Biomarkers could behave differently depending on EF type. Here, we analyze the soluble form of the AXL receptor tyrosine kinase (sAXL) in HF patients with reduced and preserved EF. Two groups of HF patients with reduced (HFrEF; n = 134) and preserved ejection fraction (HFpEF; n = 134) were included in this prospective observational study, with measurements of candidate biomarkers and functional, clinical, and echocardiographic variables. A Cox regression model was used to determine predictors for clinical events: cardiovascular mortality and all-cause mortality. sAXL circulating values predicted outcome in HF: for a 1.0 ng/mL increase in serum sAXL, the mortality hazard ratio (HR) was 1.019 for HFrEF (95% CI 1.000 to 1.038) and 1.032 for HFpEF (95% CI 1.013 to 1.052). In a multivariable Cox regression analysis, sAXL and NT-proBNP were independent markers for all-cause and cardiovascular mortality in HFpEF. In contrast, only NT-proBNP remained significant in the HFrEF group. When analyzing the event-free survival at a mean follow-up of 3.6 years, HFrEF and HFpEF patients in the higher quartile of sAXL had a reduced survival time. Interestingly, sAXL is a reliable predictor for all-cause and cardiovascular mortality only in the HFpEF cohort. The results suggest an important role for AXL in HFpEF, supporting sAXL evaluation in larger clinical studies and pointing to AXL as a potential target for HF therapy., This research was funded by: Ministerio de Ciencia e Innovación (Projects# RTI2018-095672-B-I00 and PID2021-123564OB-I00 to P.G.d.F. and A.M.) co-funded by European Union (ERDF “A way to make Europe”); Consejo Superior de Investigaciones Científicas (AEPP2021) and Fundació la Marató de TV3 (202133-32) to P.G.d.F and A.M.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Induction of the inflammasome pathway by tyrosine kinase inhibitors provides an actionable therapeutic target for hepatocellular carcinoma

  • Tutusaus, Anna
  • Sanduzzi Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell, Anna
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Prognostic Value of Soluble AXL in Serum from Heart Failure Patients with Preserved and Reduced Left Ventricular Ejection Fraction

  • Cristóbal, Helena
  • Enjuanes Cristina
  • Batlle, Montserrat
  • Tajes, Marta
  • Campos, Begoña
  • Francesch, Josep
  • Moliner, Pedro
  • Farrero, Marta
  • Andrea, Rut
  • Ortiz-Pérez, José T.
  • Morales, Albert
  • Sabaté, Manel
  • Comin-Colet, Josep
  • García de Frutos, Pablo
Heart failure (HF) is classified according to the degree of reduction in left ventricular ejection fraction (EF) in HF with reduced, mildly reduced, and preserved EF. Biomarkers could behave differently depending on EF type. Here, we analyze the soluble form of the AXL receptor tyrosine kinase (sAXL) in HF patients with reduced and preserved EF. Two groups of HF patients with reduced (HFrEF; n = 134) and preserved ejection fraction (HFpEF; n = 134) were included in this prospective observational study, with measurements of candidate biomarkers and functional, clinical, and echocardiographic variables. A Cox regression model was used to determine predictors for clinical events: cardiovascular mortality and all-cause mortality. sAXL circulating values predicted outcome in HF: for a 1.0 ng/mL increase in serum sAXL, the mortality hazard ratio (HR) was 1.019 for HFrEF (95% CI 1.000 to 1.038) and 1.032 for HFpEF (95% CI 1.013 to 1.052). In a multivariable Cox regression analysis, sAXL and NT-proBNP were independent markers for all-cause and cardiovascular mortality in HFpEF. In contrast, only NT-proBNP remained significant in the HFrEF group. When analyzing the event-free survival at a mean follow-up of 3.6 years, HFrEF and HFpEF patients in the higher quartile of sAXL had a reduced survival time. Interestingly, sAXL is a reliable predictor for all-cause and cardiovascular mortality only in the HFpEF cohort. The results suggest an important role for AXL in HFpEF, supporting sAXL evaluation in larger clinical studies and pointing to AXL as a potential target for HF therapy., This research was funded by: Ministerio de Ciencia e Innovación (Projects# RTI2018-095672-B-I00 and PID2021-123564OB-I00 to P.G.d.F. and A.M.) co-funded by European Union (ERDF “A way to make Europe”); Consejo Superior de Investigaciones Científicas (AEPP2021) and Fundació la Marató de TV3 (202133-32) to P.G.d.F and A.M.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice

  • Cuño-Gómiz, Carlos
  • Gregorio, Estefanía de
  • Tutusaus, Anna
  • Rider, Patricia
  • Andrés-Sánchez, Nuria
  • Colell Riera, Anna
  • Morales, Albert
  • Marí, Montserrat
Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in Western countries, evolving into metabolic dysfunction-associated steatohepatitis (MASH) with a sexual dimorphism. Fertile women exhibit lower MASLD risk than men, which diminishes post-menopause. While NKT-cell involvement in steatohepatitis is debated, discrepancies may stem from varied mouse strains used, predominantly C57BL6/J with Th1-dominant responses. Exploration of steatohepatitis, encompassing both genders, using Balb/c background, with Th2-dominant immune response, and CD1d-deficient mice in the Balb/c background (lacking Type I and Type II NKT cells) can clarify gender disparities and NKT-cell influence on MASH progression., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study has been funded by Instituto de Salud Carlos III (ISCIII) through projects PI19/01410 and PI22/00475 to M.M., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD and CIBERNED; grant numbers PID2021-123564OB-I00 to A.M and grant PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/ 0.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma

  • Tutusaus, Anna
  • Sanduzzi-Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell Riera, Anna
  • Marí, Montserrat
  • Reig, Maria
  • Morales, Albert
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Simple Summary: In the past decade, tyrosine kinase inhibitors sorafenib and regorafenib have been standard treatments for advanced liver cancer. Previous studies have associated sorafenib with inflammasome activation, but its therapeutic role in patients has not been explored. Our study found that both treatments altered inflammasome-related gene expression, showing a similar transcriptomic pattern in a mouse model of liver cancer. In accordance with public databases, inflammasome genes are associated with a poorer prognosis in male liver cancer patients, without changes in females. Thus, we analyzed biopsies from hepatocellular carcinoma patients treated with sorafenib/regorafenib and confirmed inflammasome activation. In experimental models, inflammasome inhibition enhanced sorafenib effectiveness, demonstrating its potential to overcome therapy resistance and improve its efficacy for liver cancer treatment., Abstract: During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

GAS6/TAM Axis as Therapeutic Target in Liver Diseases

  • Tutusaus, Anna
  • Morales, Albert
  • García de Frutos, Pablo
  • Marí, Montserrat
TAM (TYRO3, AXL, and MERTK) protein tyrosine kinase membrane receptors and their vitamin K-dependent ligands GAS6 and protein S (PROS) are well-known players in tumor biology and autoimmune diseases. In contrast, TAM regulation of fibrogenesis and the inflammation mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and, ultimately, liver cancer has recently been revealed. GAS6 and PROS binding to phosphatidylserine exposed in outer membranes of apoptotic cells links TAMs, particularly MERTK, with hepatocellular damage. In addition, AXL and MERTK regulate the development of liver fibrosis and inflammation in chronic liver diseases. Acute hepatic injury is also mediated by the TAM system, as recent data regarding acetaminophen toxicity and acute-on-chronic liver failure have uncovered. Soluble TAM-related proteins, mainly released from activated macrophages and hepatic stellate cells after hepatic deterioration, are proposed as early serum markers for disease progression. In conclusion, the TAM system is becoming an interesting pharmacological target in liver pathology and a focus of future biomedical research in this field., This research was funded by Instituto de Salud Carlos III (Project# PI22/00475 to M.M.) and by Ministerio de Ciencia e Innovación (PID2021-123564OB-I00, MCIN/AEI/10.13039/501100011033 to A.M. and P.G.F.), and co-funded by the European Union “ERDF A Way of Making Europe” (Next Generation EU/PRTR); CIBERCV; AGAUR (2021_SGR_490) and CERCA Programme/Generalitat de Catalunya; and Fundació la Marató de TV3 (202133-32) to A.M. and P.G.F. This research also received research funding and Sponsored Research Agreement, from BerGenBio ASA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hallmarks of pancreatic cancer: spotlight on TAM receptors

  • Vázquez-Bellón, Núria
  • Martínez-Bosch, Neus
  • García de Frutos, Pablo
  • Navarro Medrano, Pilar
Pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent type of pancreatic cancer and ranks among the most aggressive tumours, with a 5-year survival rate of less than 11%. Projections indicate that by 2030, it will become the second leading cause of cancer-related deaths. PDAC presents distinctive hallmarks contributing to its dismal prognosis: (i) late diagnosis, (ii) heterogenous and complex mutational landscape, (iii) high metastatic potential, (iv) dense fibrotic stroma, (v) immunosuppressive microenvironment, and (vi) high resistance to therapy. Mounting evidence has shown a role for TAM (Tyro3, AXL, MerTK) family of tyrosine kinase receptors in PDAC initiation and progression. This review aims to describe the impact of TAM receptors on the defining hallmarks of PDAC and discuss potential future directions using these proteins as novel biomarkers for early diagnosis and targets for precision therapy in PDAC, an urgent unmet clinical need., This work was supported by grants from the Spanish Ministry of Science, Innovation and Universities (MICIU)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF “A way of making Europe”) (PI20/00625 and PI23/00591) to PN, 8th “Beca Carmen Delgado” to PN and PGF and grants from the MICIU (PID2021-123564OB-100) to PGF. The funders did not have any role in paper design, data collection, data analysis, interpretation, or writing of the paper. NV-B is supported by a FPU (“Formación de Profesorado Universitario”) predoctoral contract from the MICIU (FPU21/0928). The authors did not receive remuneration for their participation. We thank TPM Science for English proofreading and manuscript editing., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroinflammation in Age-Related Neurodegenerative Diseases: Role of Mitochondrial Oxidative Stress

  • Abadin, Xenia
  • Dios, Cristina de
  • Zubillaga, Marlene
  • Ivars, Elia
  • Puigros Serra, Margalida
  • Marí, Montserrat
  • Morales, Albert
  • Vizuete, Marisa
  • Vitorica, Javier
  • Trullas, Ramón
  • Colell Riera, Anna
  • Roca-Agujetas, Vicente
A shared hallmark of age-related neurodegenerative diseases is the chronic activation of innate immune cells, which actively contributes to the neurodegenerative process. In Alzheimer's disease, this inflammatory milieu exacerbates both amyloid and tau pathology. A similar abnormal inflammatory response has been reported in Parkinson's disease, with elevated levels of cytokines and other inflammatory intermediates derived from activated glial cells, which promote the progressive loss of nigral dopaminergic neurons. Understanding the causes that support this aberrant inflammatory response has become a topic of growing interest and research in neurodegeneration, with high translational potential. It has been postulated that the phenotypic shift of immune cells towards a proinflammatory state combined with the presence of immunogenic cell death fuels a vicious cycle in which mitochondrial dysfunction plays a central role. Mitochondria and mitochondria-generated reactive oxygen species are downstream effectors of different inflammatory signaling pathways, including inflammasomes. Dysfunctional mitochondria are also recognized as important producers of damage-associated molecular patterns, which can amplify the immune response. Here, we review the major findings highlighting the role of mitochondria as a checkpoint of neuroinflammation and immunogenic cell deaths in neurodegenerative diseases. The knowledge of these processes may help to find new druggable targets to modulate the inflammatory response., This research was funded by MCIN/AEI/10.13039/501100011033, co-funded by NextGenera-tionEU/PRTR, and by “ERDF A way of making Europe”, grants PID2022-143279OB-100 (A.C.), PID2021-123564OB-100 (A.M.), PDC2023-145806-100 (A.M and M.M.), PID2020-115091RB-I00 (R.T.), and RED2022-134786-T (A.C. and R.T.); Instituto de Salud Carlos III (ISCIII) and European Union NextGenerationEU/PRTR, grants PMP22/00100 (R.T. and A.C.) and PI22/00475 (M.M.); Fundació la Marató de TV3 (A.M.); AGAUR, grant 2021-SGR00490 (A.C.); and Junta de Andalucia (Consejería de Economia y Conocimiento) co-funded by FEDER 214-2020 and by the CIBERNED (Convocatoria 2022 Proyectos Colaborativos 2020/21), grants US-1262734 (J.V.) and P20-00843 (J.V.). V.R.-A. has a Juan de la Cierva postdoctoral contract (JDC2022-048952-I) funded by MCIN/AEI/10.13039/501100011033 and by NextGenerationEU/PRTR. C.D. has a contract (2022 INV-1 00065) funded by “Programa Investigo” MCIN/PRTR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

  • Grøndal, Sturla Magnus
  • Tutusaus, Anna
  • Boix, Loreto
  • Reig, Maria
  • Blø, Magnus
  • Hodneland, Linn
  • Gausdal, Gro
  • Jackson, Akil
  • García de Frutos, Pablo
  • Lorens, James Bradley
  • Morales, Albert
  • Marí, Montserrat
Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health concern with limited treatment options. AXL, a receptor tyrosine kinase activated by the GAS6 ligand, promotes MASH through activation of hepatic stellate cells and inflammatory macrophages. This study identified cell subsets affected by MASH progression and the effect of AXL inhibition., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Projects# RTI2018–095672-B-I00 and PID2021–123564OB-I00 to AM and PG funded by MCIN/AEI/10.13039/501100011033 and co-funded by “ERDF A way of making Europe”. Project# PI19/01410 and PI22/00475 to MM funded by Instituto de Salud Carlos III and co-funded by the European Union “ERDF A way of making Europe”; AGAUR (2021_SGR_490) and CERCA Programme/Generalitat de Catalunya, and Fundació la Marató de TV3 (202133–32)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages

  • Fuster-Anglada, Carla
  • Corominas, Josep
  • Marsal, Aida
  • Llarch, Neus
  • Iserte, Gemma
  • Sanduzzi-Zamparelli, Marco
  • Forner, Alejandro
  • Ferrer-Fábrega, Joana
  • Holguin, Víctor Emilio
  • Morales, Albert
  • Saavedra, Carolina
  • Reig, Maria
  • Boix, Loreto
  • Marí, Montserrat
  • Díaz, Alba
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy. However, their efficacy in hepatocellular carcinoma (HCC) is limited, highlighting the need to further explore immune microenvironments and novel biomarkers. This study examined lymphocyte populations and immune checkpoint dynamics in early, advanced, and post-progression HCC to better understand immune dynamics in HCC and to help identify predictive biomarkers and immune modulation strategies., The author(s) declare that financial support was received for the research and/or publication of this article. Premi final de residencia “Emili Letang-Josep Font” to CF-A. This research was funded by Instituto de Salud Carlos III (ISCIII) through projects PI22/01427 to MR, PI22/00475 to MM, MCIN/AEI/10.13039/501100011033, PID2021-123564OB-100 and PDC2023-145806–100 to AM, and co-funded by NextGenerationEU/PRTR, and by “ERDF A way of making Europe”; CIBEREHD; MSZ: received grant support from Instituto de Salud Carlos III (FI19/00222) and from CIBEREHD (CIBER/EHD25PI02)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immune remodeling via mitochondria-dependent STING activation enhances cabozantinib response in hepatocellular carcinoma

  • Rider, Patricia
  • Tutusaus, Anna
  • Cuño-Gómiz, Carlos
  • Savino, Flavia
  • Marsal, Aida
  • Llarch, Neus
  • Iserte, Gemma
  • Colell, Anna
  • García de Frutos, Pablo
  • Hernáez-Alsina, Tania
  • Sanduzzi-Zamparelli, Marco
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
BACKGROUND: Cabozantinib, a tyrosine kinase inhibitor (TKI) approved for advanced hepatocellular carcinoma (HCC), has established clinical benefit although the underlying immunomodulatory mechanisms, particularly those involving mitochondrial stress and the cGAS/STING pathway, remain poorly defined. METHODS: We assessed cabozantinib’s effects on mitochondrial integrity and innate immune signaling in hepatoma cells and macrophage cell lines, analyzing mitochondrial depolarization, reactive oxygen species production, cytosolic release of mitochondrial DNA (mtDNA), activation of the cGAS/STING pathway and induction of type I interferon-stimulated genes (ISGs). Functional relevance was tested by mtDNA depletion and CRISPR-mediated STING knockdown. The in vivo effects of cabozantinib and the STING agonist DMXAA were examined in immunocompetent mouse models. Translational relevance was evaluated by multiplex proteomic profiling of serum samples from 18 cabozantinib-treated HCC patients across two independent cohorts. RESULTS: Cabozantinib induced mitochondrial depolarization, oxidative stress, and cytosolic mtDNA release, resulting in STING-dependent signaling and ISG upregulation in hepatoma cells. Disruption of mtDNA or STING abrogated these effects. In vivo, cabozantinib reduced tumor growth and promoted tumor-infiltrating lymphocyte activation, which were further enhanced by DMXAA co-treatment. Patient serum proteomics revealed consistent increases in immune and stress-related proteins (e.g., granzyme B, HO-1, CAIX, CXCL13) and decreases in angiogenic and immunosuppressive factors (e.g., VEGFR-2, ANGPT1/2, CCL17), paralleling the systemic immune remodeling observed in preclinical models. Both baseline immune signatures and treatment-induced protein shifts were associated with clinical outcome. CONCLUSIONS: Cabozantinib promotes tumor immunogenicity through mitochondrial disruption and cGAS/STING activation, leading to immune remodeling in HCC. These findings provide mechanistic insight into the immunomodulatory effects of cabozantinib, support rational combinations with STING agonists, and highlight candidate biomarkers for predicting therapeutic response in TKI-treated patients., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Projects# PID2022-143279OB-100 to AC, PID2021–123564OB-I00 and PDC2023-145806-100 to AM and PG funded by MCIN/AEI/10.13039/501100011033 and co-funded by “ERDF A way of making Europe” and PERTE-CHIP program. Project# PI22/00475 and PI25/00398 to MM and PI22/01427 to MR funded by Instituto de Salud Carlos III and co-funded by the European Union “ERDF A way of making Europe”; AGAUR (2021_SGR_490) and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Picrosirius red, polarized light microscopy, and curvelet transform analysis: An improved method for liver fibrosis assessment

  • Cuño-Gómiz, Carlos
  • Tutusaus, Anna
  • Savino, Flavia
  • Rider, Patricia
  • Colell, Anna
  • Morales, Albert
  • Marí, Montserrat
Liver fibrosis is a hallmark of chronic liver diseases, characterized by excessive extracellular matrix deposition and structural alterations. Conventional histological assessments rely on qualitative or semi-quantitative scoring systems that may lack sensitivity for subtle fibrotic changes. Here, we present an improved fibrosis evaluation method integrating Picrosirius Red (PSR) staining, polarized light (PL) microscopy, and curvelet transform-based fiber analysis (CT-FIRE). This approach provides a quantitative and reproducible assessment of collagen fiber morphology and composition. Applied to murine models of metabolic dysfunction-associated steatohepatitis (MASH)-induced fibrosis, our method reveals novel insights into fibrosis progression and strain-dependent variations. This enhanced workflow offers a cost-effective, high-resolution tool for fibrosis analysis in preclinical research., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021–123564OB-I00 and PDC2023–145806-I00 to A.M, PID2022–143279OB-100 to A.C., funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Induction of the inflammasome pathway by tyrosine kinase inhibitors provides an actionable therapeutic target for hepatocellular carcinoma

  • Tutusaus, Anna
  • Sanduzzi Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell, Anna
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

  • Magnus Grøndal, Sturla
  • Tutusaus, Anna
  • Boix, Loreto
  • Reig, María
  • Blø, Magnus
  • Hodneland, Linn
  • Gausdal, Gro
  • Jackson, Akil
  • García de Frutos, Pablo
  • Lorens, James Bradley
  • Morales, Albert
  • Marí, Montserrat
Background and aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a significant health concern with limited treatment options. AXL, a receptor tyrosine kinase activated by the GAS6 ligand, promotes MASH through activation of hepatic stellate cells and inflammatory macrophages. This study identified cell subsets affected by MASH progression and the effect of AXL inhibition. Methods: Mice were fed chow or different fat-enriched diets to induce MASH, and small molecule AXL kinase inhibition with bemcentinib was evaluated. Gene expression was measured by qPCR. Time-of-flight mass cytometry (CyTOF) used single cells from dissociated livers, acquired on the Fluidigm Helios, and cell populations were studied using machine learning. Results: In mice fed different fat-enriched diets, liver steatosis alone was insufficient to elevate plasma soluble AXL (sAXL) levels. However, in conjunction with inflammation, sAXL increases, serving as an early indicator of steatohepatitis progression. Bemcentinib, an AXL inhibitor, effectively reduced proinflammatory responses in MASH models, even before fibrosis appearance. Utilizing CyTOF analysis, we detected a decreased population of Kupffer cells during MASH while promoting infiltration of monocytes/macrophages and CD8+ T cells. Bemcentinib partially restored Kupffer cells, reduced pDCs and GzmB- NK cells, and increased GzmB+CD8+ T cells and LSECs. Additionally, AXL inhibition enhanced a subtype of GzmB+CD8+ tissue-resident memory T cells characterized by CX3CR1 expression. Furthermore, bemcentinib altered the transcriptomic landscape associated with MASH progression, particularly in TLR signaling and inflammatory response, exhibiting differential cytokine expression in the plasma, consistent with liver repair and decreased inflammation. Conclusion: Our findings highlight sAXL as a biomarker for monitoring MASH progression and demonstrate that AXL targeting shifted liver macrophages and CD8+ T-cell subsets away from an inflammatory phenotype toward fibrotic resolution and organ healing, presenting a promising strategy for MASH treatment., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Projects# RTI2018–095672-B-I00 and PID2021–123564OB-I00 to AM and PG funded by MCIN/AEI/10.13039/501100011033 and co-funded by “ERDF A way of making Europe”. Project# PI19/01410 and PI22/00475 to MM funded by Instituto de Salud Carlos III and co-funded by the European Union “ERDF A way of making Europe”; AGAUR (2021_SGR_490) and CERCA Programme/Generalitat de Catalunya, and Fundació la Marató de TV3 (202133–32).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prognostic value of soluble AXL in serum from heart failure patients with preserved and reduced left ventricular ejection fraction

  • Cristóbal, Helena
  • Enjuanes Grau, Cristina
  • Batlle, Montserrat
  • Tajes Orduña, Marta
  • Campos, Begoña
  • Francesch Manzano, Josep
  • Moliner Borja, Pedro
  • Farrero, Marta
  • Andrea, Rut
  • Ortiz-Pérez, Jose-Tomás
  • Morales, Albert
  • Sabaté, Manel
  • Comín Colet, Josep
  • García de Frutos, Pablo
Heart failure (HF) is classified according to the degree of reduction in left ventricular ejection fraction (EF) in HF with reduced, mildly reduced, and preserved EF. Biomarkers could behave differently depending on EF type. Here, we analyze the soluble form of the AXL receptor tyrosine kinase (sAXL) in HF patients with reduced and preserved EF. Two groups of HF patients with reduced (HFrEF; n = 134) and preserved ejection fraction (HFpEF; n = 134) were included in this prospective observational study, with measurements of candidate biomarkers and functional, clinical, and echocardiographic variables. A Cox regression model was used to determine predictors for clinical events: cardiovascular mortality and all-cause mortality. sAXL circulating values predicted outcome in HF: for a 1.0 ng/mL increase in serum sAXL, the mortality hazard ratio (HR) was 1.019 for HFrEF (95% CI 1.000 to 1.038) and 1.032 for HFpEF (95% CI 1.013 to 1.052). In a multivariable Cox regression analysis, sAXL and NT-proBNP were independent markers for all-cause and cardiovascular mortality in HFpEF. In contrast, only NT-proBNP remained significant in the HFrEF group. When analyzing the event-free survival at a mean follow-up of 3.6 years, HFrEF and HFpEF patients in the higher quartile of sAXL had a reduced survival time. Interestingly, sAXL is a reliable predictor for all-cause and cardiovascular mortality only in the HFpEF cohort. The results suggest an important role for AXL in HFpEF, supporting sAXL evaluation in larger clinical studies and pointing to AXL as a potential target for HF therapy., This research was funded by: Ministerio de Ciencia e Innovación (Projects# RTI2018-095672-B-I00 and PID2021-123564OB-I00 to P.G.d.F. and A.M.) co-funded by European Union (ERDF “A way to make Europe”); Consejo Superior de Investigaciones Científicas (AEPP2021) and Fundació la Marató de TV3 (202133-32) to P.G.d.F and A.M.